Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Functional Neuromodulation Ltd.

www.functionalneuromodulation.com

Latest From Tryton Medical Inc.

US Approvals Analysis: FDA Delivers Strong Half-Year Volumes

US FDA Device-approval volumes were strong during the first half of 2017 for all review pathways. Medtronic and Siemens have so far captured the most 510(k) clearances, with Cook close behind. That and more from Medtech Insight's Approvals Tracker.

Approvals Innovation

Device Debuts: Tryton, Myriad Genetics, Integra Lifesciences, Acelity, And Toyota

This edition of device debuts highlights a wide variety of innovative devices introduced into commercial markets since the beginning of March, including a new stent for side-branch coronary interventions, an assay that identifies which breast-cancer patients do not need chemotherapy, a full ankle prosthesis, improvements to a negative-pressure wound therapy system, and a robotic system that helps paralyzed people learn to walk again.

Research & Development Clinical Trials

US Approvals Analysis: Biotronik Making Its Interventional Mark

The German-headquartered firm is making a play to enter the US vascular intervention market, with two stents approved by FDA under original PMAs in the first quarter of 2017. Cardiovascular devices, in general, have gained the most novel-device approvals so far this year, followed by IVDs. Check out more from a Q1 look at US FDA approvals and clearances monitored by Medtech Insight's Approvals Tracker.

Cardiology Cancer

US Approvals Analysis: Strong Month For IVD De Novos In February

FDA's increasingly popular de novo classification pathway for moderate-risk devices that have no predicate accounted for five marketing go-aheads last month, four of which were for in vitro diagnostics.

In Vitro Diagnostics Cardiology
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Functional Neuromodulation Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Functional Neuromodulation Ltd.
  • Senior Management
  • Daniel O'Connell, CEO
    Andres M Lozano, MD, PhD, Scientific Founder
  • Contact Info
  • Functional Neuromodulation Ltd.
    Phone: (434) 242-0571
    200 Front St. W.
    Ste. 3004
    P.O. Box 31 Toronto, M5V 3K2
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register